IRVINE, CA / ACCESSWIRE / February 27, 2017 / Khang & Khang LLP (the "Firm") announces that it is filing a class action lawsuit against Agile Therapeutics, Inc. ("Agile" or the "Company") (NASDAQ: AGRX) concerning possible violations of federal securities laws, on behalf of investors who purchased or otherwise acquired Agile shares between March 9, 2016 and January 3, 2017 inclusive (the "Class Period"). Those who suffered a loss during the class period are encouraged to contact the firm in advance of the March 7, 2017 lead plaintiff motion deadline.
If you purchased shares of Agile and would like more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
Agile is a pharmaceutical company that develops and markets prescription female contraceptive products.
On January 3, 2017, Agile revealed new information related to its Phase 3 SECURE study assessing Agile's combined hormonal contraceptive patch product, Twirla. The FDA wanted the study after it rejected Agile's initial marketing application in 2013. The Company stated that 2% of study participants suffered "serious adverse events," including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy, and depression." Furthermore, 51.4% of subjects left the study. When this information was revealed to the public, the value of Agile stock fell sharply, causing investors harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.
Contact:
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
SOURCE: Khang & Khang LLP
ReleaseID: 456107
